Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming

Hepatocellular carcinoma (HCC) represents an important challenge for global health. Recent findings showed that systemic or local hypothyroidism is associated with HCC development. In rat models, we showed that T3 administration impaired HCC progression, even when given at late stages, most likely by prompting a differentiation program and a metabolic switch. This is relevant from a translational point of view as HCC is often diagnosed at an advanced stage when it is no longer amenable to curative treatments. Thyroid hormone and/or thyromimetics could improve the prognosis of HCC patients.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research